| Erlotinib | IC50 | 300.0 [1] |
| Lapatinib | IC50 | 10.2 [1] |
| Gefitinib | IC50 | 343.0 [1] |
| Canertinib | IC50 | 30.0 [1] |
| Tykerb | IC50 | 9.0 [1] |
| Cudc-101 | IC50 | 15.7 [1], 16.4 [2], 100.0 [3], 188.0 [4] |
| Ibrutinib | IC50 | 1.5 [1], 9.4 [2] |
| Neratinib | IC50 | 1.0 [1], 59.0 [2] |
| 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline | IC50 | 5.7 [1], 24.0 [2], 114.0 [3] |
| Sapitinib | IC50 | 3.0 [1], 14.0 [2], 60.0 [3] |
| [(3R,5S)-5-[2-[4-[3-Chloro-4-[(3-fluorophenyl)methoxy]anilino]thieno[3,2-d]pyrimidin-6-yl]ethynyl]pyrrolidin-3-yl] morpholine-4-carboxylate | IC50 | 50.0 [1], 80.0 [2], 84.0 [3] |
| Staurosporine | IC50 | 34.0 [1], 60.8 [2], 115.0 [3] |
| Tyrphostin B42 | IC50 | 13489.63 [1], 13500.0 [2] |
| Afatinib | IC50 | 2.0 [1], 14.0 [2], 17.3 [3] |
| Dacomitinib | IC50 | 16.7 [1], 45.7 [2], 46.0 [3] |
| Pelitinib | IC50 | 1229.0 [1], 1230.0 [2] |
| Tyrphostin AG 555 | IC50 | 34673.69 [1], 35000.0 [2] |
| Tyrphostin B56 | IC50 | 500000.0 [1], 501187.23 [2] |
| N6,N6-Dimethyl-N4-[1-(phenylmethyl)-5-indazolyl]pyrido[3,4-d]pyrimidine-4,6-diamine | IC50 | 16.0 [1], 70.0 [2], 97.0 [3] |
| Tak-285 | IC50 | 3.0 [1], 17.0 [2] |
| Tyrphostin B48 | IC50 | 41686.94 [1], 42000.0 [2] |
| Tyrphostin AG 698 | IC50 | 22908.68 [1], 23000.0 [2] |
| 3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)pyrrole-2,5-dione | IC50 | 13100.0 [1], 26000.0 [2], 50000.0 [3] |
| N-[1-[(3-Fluorophenyl)methyl]indazol-5-yl]-5-[[(2S)-morpholin-2-yl]methoxymethyl]pyrrolo[2,1-f][1,2,4]triazin-4-amine | IC50 | 55.0 [1] |
| Tyrphostin deriv. 36 | IC50 | 34673.69 [1], 35000.0 [2] |
| [(3R,5S)-5-[2-[4-[3-Chloro-4-[(3-fluorophenyl)methoxy]anilino]thieno[3,2-d]pyrimidin-6-yl]ethynyl]pyrrolidin-3-yl] N,N-dimethylcarbamate | IC50 | 10.0 [1], 68.0 [2] |
| [(3R,5S)-5-[2-[4-[3-Chloro-4-[(3-fluorophenyl)methoxy]anilino]thieno[3,2-d]pyrimidin-6-yl]ethynyl]pyrrolidin-3-yl] N-ethylcarbamate | IC50 | 10.0 [1], 43.0 [2] |
| (2R)-N,N-Dimethyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide | IC50 | 1.0 [1], 23.0 [2] |
| 4-(1-(3-Fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime | IC50 | 12.0 [1], 301.0 [2] |
| N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-5-(4-methylpiperazin-1-yl)pent-2-ynamide | IC50 | 0.7 [1], 0.8 [2], 1.0 [3] |
| N-[4-[4-Amino-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-chloro-1,3-benzoxazol-2-amine | IC50 | 7.5 [1], 200.0 [2], 340.0 [3] |
| 4-[(1-Benzylindazol-5-yl)amino]-5-ethyl-N-(3-imidazol-1-ylpropyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide | IC50 | 30.0 [1], 5800.0 [2], 7000.0 [3] |
| 3-Imidazol-1-ylpropyl 4-[(1-benzylindazol-5-yl)amino]-5-ethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate | IC50 | 240.0 [1], 1600.0 [2], 3100.0 [3] |
| 4-[4-[3-Chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]-N-(2-methylsulfonylethyl)-1,3-thiazol-2-amine | IC50 | 14.0 [1], 110.0 [2], 130.0 [3] |
| 4-[4-[(1-Benzylindazol-5-yl)amino]quinazolin-6-yl]-N-(2-methylsulfonylethyl)-1,3-thiazol-2-amine | IC50 | 28.0 [1], 60.0 [2], 90.0 [3] |
| 4-[4-(3-Chloro-4-phenylmethoxyanilino)quinazolin-6-yl]-N-(2-methylsulfonylethyl)-1,3-thiazol-2-amine | IC50 | 14.0 [1], 280.0 [2], 360.0 [3] |
| 4-[4-(3-Chloro-4-fluoroanilino)quinazolin-6-yl]-N-(2-methylsulfonylethyl)-1,3-thiazol-2-amine | IC50 | 200.0 [1], 2400.0 [2], 4400.0 [3] |
| N-(2-Methylsulfonylethyl)-4-[4-(4-phenylmethoxyanilino)quinazolin-6-yl]-1,3-thiazol-2-amine | IC50 | 48.0 [1], 860.0 [2], 1500.0 [3] |
| N-(2-Methylsulfonylethyl)-4-[4-[4-[[3-(trifluoromethyl)phenyl]methoxy]anilino]quinazolin-6-yl]-1,3-thiazol-2-amine | IC50 | 550.0 [1], 7400.0 [2], 15000.0 [3] |
| N-[4-[4-Amino-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-7-chloro-1,3-benzoxazol-2-amine | IC50 | 16.0 [1], 362.0 [2], 1350.0 [3] |
| 2-Imidazol-1-ylethyl N-[4-[(1-benzylindazol-5-yl)amino]-5-ethylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate | IC50 | 40.0 [1], 460.0 [2], 860.0 [3] |
| Erlotinib hydrochloride | IC50 | 1520.0 [1], 1890.0 [2] |
| Dasatinib | IC50 | 710.0 [1] |
| Nintedanib | IC50 | 10000.0 [1], 50000.0 [2] |
| N-(4-((3-Bromophenyl)amino)quinazolin-6-yl)but-2-ynamide | IC50 | 17.0 [1], 378.0 [2] |
| Tyrphostin A46 | IC50 | 6400.0 [1], 6456.54 [2] |
| Tyrphostin AG 538 | IC50 | 16982.44 [1], 18000.0 [2] |
| Falnidamol | IC50 | 3.0 [1], 3400.0 [2] |
| PDGF Receptor Tyrosine Kinase Inhibitor IV | IC50 | 10000.0 [1] |
| CID 9874913 | IC50 | 10.0 [1], 12.0 [2] |
| Bms-599626 | IC50 | 22.0 [1], 23.0 [2] |
| N-(2,6-Difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl]-2-methoxybenzamide | IC50 | 1000.0 [1], 10000.0 [2] |
| Tyrphostin AG 528 | IC50 | 4897.79 [1], 4900.0 [2] |
| EGFR/ErbB-2/ErbB-4 Inhibitor | IC50 | 1.1 [1], 24.0 [2] |
| N-(2-Chloro-6-methylphenyl)-2-[(2,6-dimethylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide | IC50 | 500.0 [1], 5200.0 [2] |
| 6-Alkoxy-4-anilinoquinazoline 8b | IC50 | 234.0 [1], 1680.0 [2] |
| (E)-N-[4-(3-Bromoanilino)-3-cyano-8-methoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide | IC50 | 9300.0 [1], 9350.0 [2] |
| N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(1H-pyrrol-2-yl)thieno[3,2-d]pyrimidin-4-amine | IC50 | 121.0 [1], 826.0 [2] |
| Unii-W39547M0FP | IC50 | 8.0 [1], 11.0 [2] |
| 4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(1-methylpiperidin-4-yloxy)quinazoline | IC50 | 2.0 [1], 61.0 [2] |
| (6S,7S)-N-Hydroxy-6-(4-phenyl-3,6-dihydro-2H-pyridine-1-carbonyl)-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 18.0 [1] |
| (6S,7S)-N-Hydroxy-6-[(4-phenylpiperazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 52.0 [1] |
| CID 44446843 | IC50 | 358.0 [1], 359.0 [2] |
| Tyrphostin deriv. 25 | IC50 | 12882.5 [1], 13600.0 [2] |
| Tyrphostin deriv. 28 | IC50 | 10000.0 [1] |
| Tyrphostin deriv. 29 | IC50 | 18000.0 [1], 18197.01 [2] |
| Tyrphostin deriv. 30 | IC50 | 12000.0 [1], 12022.64 [2] |
| Tyrphostin deriv. 33 | IC50 | 3000.0 [1], 3019.95 [2] |
| N-[4-(3-Chloro-4-fluoro-phenylamino)-quinazolin-6-yl]-acrylamide | IC50 | 4.3 [1] |
| N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide | IC50 | 2.2 [1], 22.0 [2] |
| 5-[(4-Aminopiperidin-1-yl)methyl]-N-[1-[(3-fluorophenyl)methyl]indazol-5-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine | IC50 | 22.0 [1], 23.0 [2] |
| 2-(4-(4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)acetamide | IC50 | 46.0 [1], 107.0 [2] |
| N-[4-(3-Bromo-4-fluoro-phenylamino)-quinazolin-6-yl]-acrylamide | IC50 | 7.3 [1] |
| N-[4-(3-Chloro-4-fluoro-phenylamino)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide | IC50 | 12.0 [1] |
| (E)-N-[4-[3-Chloro-4-[(3-chlorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide | IC50 | 8.0 [1] |
| (E)-N-[4-[3-Chloro-4-[(4-phenyl-1,3-thiazol-2-yl)sulfanyl]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide | IC50 | 13.0 [1] |
| (E)-N-[4-[3-Chloro-4-[(5-phenyl-1,3-thiazol-2-yl)sulfanyl]anilino]-3-cyano-7-methoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide | IC50 | 1000.0 [1], 1007.0 [2] |
| [4-[3-Chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]urea | IC50 | 26.8 [1], 287.0 [2] |
| (6S,7S)-N-Hydroxy-6-{[(3R)-3-phenylpyrrolidin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 92.0 [1] |
| (6S,7S)-N-Hydroxy-5-methyl-6-[(4-phenylpiperazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 230.0 [1] |
| (E)-2-Cyano-N-cyclohexyl-3-(3,4-dihydroxyphenyl)prop-2-enamide | IC50 | 16982.44 [1], 17000.0 [2] |
| [(3R,5S)-5-[2-[4-[3-Chloro-4-[(3-fluorophenyl)methoxy]anilino]thieno[3,2-d]pyrimidin-6-yl]ethynyl]pyrrolidin-3-yl] N-methylcarbamate | IC50 | 20.0 [1] |
| N-(4-(3-Fluorobenzyloxy)-3-chlorophenyl)pyrimidin-4-amine | IC50 | 21000.0 [1], 25000.0 [2] |
| N-[1-[(3-Fluorophenyl)methyl]indazol-5-yl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-amine | IC50 | 88.0 [1] |
| N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[[(2S)-morpholin-2-yl]methoxymethyl]pyrrolo[2,1-f][1,2,4]triazin-4-amine | IC50 | 560.0 [1] |
| N-[1-[(3-Fluorophenyl)methyl]indazol-5-yl]-6-methoxy-5-[[(2S)-morpholin-2-yl]methoxymethyl]pyrrolo[2,1-f][1,2,4]triazin-4-amine | IC50 | 250.0 [1] |
| N-[3-[5-[2-(3-Morpholin-4-ylanilino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-phenylacetamide | IC50 | 73.0 [1], 680.0 [2] |
| 2-(2-Methyl-5-nitroimidazol-1-yl)ethyl (E)-3-(4-phenylphenyl)prop-2-enoate | IC50 | 2150.0 [1] |
| Tyrphostin deriv. 39 | IC50 | 50000.0 [1], 50118.72 [2] |
| Tyrphostin deriv. 54 | IC50 | 57000.0 [1], 57543.99 [2] |
| Tyrphostin deriv. 58 | IC50 | 331131.12 [1], 333000.0 [2] |
| Tyrphostin deriv. 64 | IC50 | 165958.69 [1], 166000.0 [2] |
| Tyrphostin deriv. 70 | IC50 | 33884.42 [1], 34000.0 [2] |
| 4-Anilinoquinazoline deriv. 10n | IC50 | 9.0 [1], 122.0 [2] |
| 6-Alkoxy-4-anilinoquinazoline 8c | IC50 | 210.0 [1], 1380.0 [2] |
| 6-Alkoxy-4-anilinoquinazoline 8f | IC50 | 19.0 [1], 390.0 [2] |
| 6,6-Dimethyl-8-[1-(oxetan-3-yl)piperidin-4-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile | IC50 | 50000.0 [1] |
| (E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(1-phenylethyl)prop-2-enamide | IC50 | 37000.0 [1], 37153.52 [2] |
| 7,8-Dichloro-9-methyl-1-oxospiro[2,4-dihydropyrido[3,4-b]indole-3,4'-piperidine]-4-carbonitrile | IC50 | 10000.0 [1] |
| 2-[4-[3-Chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethanol | IC50 | 12.0 [1] |